Ares Commercial Real Estate Corp Annual Income Tax Expense (Benefit) in USD from 2013 to 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary
Ares Commercial Real Estate Corp quarterly/annual Income Tax Expense (Benefit) history and growth rate from 2013 to 2023.
  • Ares Commercial Real Estate Corp Income Tax Expense (Benefit) for the quarter ending September 30, 2024 was -$3K, a 81.3% increase year-over-year.
  • Ares Commercial Real Estate Corp Income Tax Expense (Benefit) for the twelve months ending September 30, 2024 was -$88K, a 128% decline year-over-year.
  • Ares Commercial Real Estate Corp annual Income Tax Expense (Benefit) for 2023 was -$39K, a 108% decline from 2022.
  • Ares Commercial Real Estate Corp annual Income Tax Expense (Benefit) for 2022 was $472K, a 34.6% decline from 2021.
  • Ares Commercial Real Estate Corp annual Income Tax Expense (Benefit) for 2021 was $722K, a 105% increase from 2020.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Annual (USD)
Income Tax Expense (Benefit), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$39K -$511K -108% Jan 1, 2023 Dec 31, 2023 10-K 2024-02-22
2022 $472K -$250K -34.6% Jan 1, 2022 Dec 31, 2022 10-K 2024-02-22
2021 $722K +$370K +105% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-22
2020 $352K -$163K -31.7% Jan 1, 2020 Dec 31, 2020 10-K 2023-02-15
2019 $515K +$69K +15.5% Jan 1, 2019 Dec 31, 2019 10-K 2022-02-15
2018 $446K +$268K +151% Jan 1, 2018 Dec 31, 2018 10-K 2021-02-18
2017 $178K -$52K -22.6% Jan 1, 2017 Dec 31, 2017 10-K 2020-02-20
2016 $230K +$241K Jan 1, 2016 Dec 31, 2016 10-K 2019-02-21
2015 -$11K -$251K -105% Jan 1, 2015 Dec 31, 2015 10-K 2018-03-01
2014 $240K +$64K +36.4% Jan 1, 2014 Dec 31, 2014 10-K 2017-03-07
2013 $176K Jan 1, 2013 Dec 31, 2013 10-K 2016-03-01
* An asterisk sign (*) next to the value indicates that the value is likely invalid.